Prices are updated after-hours

Professional, Scientific, and Technical Services 2022 - 05 - 23

BioGaia AB/ADR

BIOGY | $12.09 0% 750

(0.0% 1d) (0.0% 1m) (13.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-50.0% volume)
Earnings Calendar:
Market Cap: $ 1,176,102,747
https://www.biogaia.se/
Sec Filling | Patents | n/a employees

(SE)

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

NEXT-ChemX Corporation.

CHMX 4 | $4.5 0% 100

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-57.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-27.54% volume)
Earnings Calendar:
Market Cap: $ 128,460,753

Sec Filling | Patents | n/a employees

(US)

add to watch list Paper trade email alert is off

3D MAKERJET, INC.

FKST | $0.65 0% 1.4K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (97.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1002.36% volume)
Earnings Calendar:
Market Cap: $ 2,287,748

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

QUANTA INC

QNTA | $0.0001 31K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-50.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (244.44% volume)
Earnings Calendar:
Market Cap: $ 50,563
http://www.quanta-inc.com/
Sec Filling | Patents | 10 employees

(US)

add to watch list Paper trade email alert is off

U.S. Stem Cell, Inc.

USRM | $0.0001 1300.0% 290K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-97.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4815.12% volume)
Earnings Calendar:
Market Cap: $ 66,151
http://us-stemcell.com/
Sec Filling | Patents | 11 employees

(United States) u.s. stem cell, inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. the company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product adipocell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. in the past 20 years, to the company’s knowledge, u.s. stem cell, inc. has completed more clinical treatments than any other regenerative care provider in the world. with more than 700 physicians trained and certified with the company, u.s. stem cell, inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

t-cell

add to watch list Paper trade email alert is off

Ehave, Inc.

EHVVF | $0.001 155.0% 34K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-54.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-86.47% volume)
Earnings Calendar:
Market Cap: $ 345,897

Sec Filling | Patents | 4 employees

ehave (ticker: ehvvf) is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. with ehave connect, ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. ehave connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by ehave and its leading partners, including multi-health systems (“mhs”), a leading publisher of psychological assessments. ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“adhd”), through its collaboration with the hospital for sick children (“sickkids”). ehave connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with medreleaf.

diagnostics

add to watch list Paper trade email alert is off

MDwerks, Inc.

MDWK | $0.21 -60.0% 2.5K

Professional, Scientific, and T...

(0.0% 1d) (-16.0% 1m) (600.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (150.0% volume)
Earnings Calendar:
Market Cap: $ 26,773,219

Sec Filling | Patents | 7 employees

learn about working at mdwerks. join linkedin today for free. see who you know at mdwerks, leverage your professional network, and get hired.

add to watch list Paper trade email alert is off

ECO INNOVATION GROUP, INC.

ECOX | $0.0002 0.0% 7M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (100.0% 7d) (-36.3% volume)
Earnings Calendar:
Market Cap: $ 486,471

Sec Filling | Patents | n/a employees

eco innovation group, inc. provides water treatment unit to convert contaminated water into safe drinking water. the company is based in palm beach, florida.

add to watch list Paper trade email alert is off

Alpha Teknova Inc

TKNO | $1.95 -2.5% -2.56% 39K

Professional, Scientific, and T...

(0.0% 1d) (-17.0% 1m) (-1.0% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (-0.87% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 79,605,605
https://www.teknova.com
Sec Filling | Patents | 193 employees

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

diagnostics gene therapies t-cell

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | News | $3.82 -2.05% -2.09% 86K

Professional, Scientific, and T...

(0.0% 1d) (-20.7% 1m) (-45.3% 1y) (0.0% 2d) (0.0% 3d) (2.6% 7d) (-63.12% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,717,592
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

1847 Holdings LLC

EFSH 4 | $2.79 17.92% 0.0% 460K

Professional, Scientific, and T...

(0.0% 1d) (1.3% 1m) (-96.7% 1y) (0.0% 2d) (0.0% 3d) (28.1% 7d) (134.46% volume)
Earnings Calendar:
Market Cap: $ 2,554,471

Sec Filling | Patents | 26 employees

1847 holdings llc, through its subsidiaries, provides a range of products and services for agriculture, construction, lawn, and garden industries in north america. it operates through two segments, land management services, and retail and appliances. the land management services segment provides waste disposal and various agricultural services, such as manure spreading, land rolling, bin whipping, cleaning of bulk storage bins and silos, equipment rental, trucking, vacuuming, building erection, various shop, and other services to local agricultural and farming communities; and wholesales agricultural equipment and parts. the retail and appliances segment provides a range of appliance services, including sales, delivery/installation, in-home service and repair, extended warranties, and financing to homeowners, builders, and designers. the company also designs, builds, and installs custom cabinetry primarily for custom and semi-custom builders. 1847 partners llc serves as the manager of

add to watch list Paper trade email alert is off

Cyclo Therapeutics Inc - Class A

CYTH | $1.26 7.94% 33K

Professional, Scientific, and T...

(0.0% 1d) (-11.9% 1m) (57.5% 1y) (0.0% 2d) (0.0% 3d) (5.0% 7d) (46.45% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 36,181,832
https://www.cyclotherapeutics.com
Sec Filling | Patents | 8 employees

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

cholesterol genetic alzheimer alzheimer’s

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $6.41 5.26% 4.99% 390K

Professional, Scientific, and T...

(0.0% 1d) (1.3% 1m) (159.1% 1y) (0.0% 2d) (0.0% 3d) (4.3% 7d) (NaN% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 277,856,597
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

iCoreConnect Inc.

ICCT | $1.09 -2.68% -3.7% 140K

Professional, Scientific, and T...

(0.0% 1d) (-7.4% 1m) (761.5% 1y) (0.0% 2d) (0.0% 3d) (-6.7% 7d) (99.28% volume)
Earnings Calendar:
Market Cap: $ 11,064,321

Sec Filling | Patents | 25 employees

icoreconnect creates software that allows anyone to share information at the highest security levels in the country, backed by highly-engaged customer support. the company provides secure communications for high-compliance industries including healthcare, finance and legal. icoreconnect’s software allows organizations and individuals to freely and easily exchange information with 2048-bit encryption, and in full compliance of current federal laws.

communication

add to watch list Paper trade email alert is off

Nukkleus Inc.

NUKK | $0.916 4.56% 93K

Professional, Scientific, and T...

(0.0% 1d) (1.1% 1m) (306566.7% 1y) (0.0% 2d) (0.0% 3d) (4.5% 7d) (378.19% volume)
Earnings Calendar:
Market Cap: $ 0
https://www.nukk.com/
Sec Filling | Patents | 1 employees

(US) nukkleus, inc. (otc: nukk) is a fintech group that acquires, builds and scales blockchain and digital financial services businesses. the portfolio serves b2b and institutional clients with the aim of disrupting the banking & investment industry for the better.

add to watch list Paper trade email alert is off

Pyxis Oncology Inc

PYXS | $4.48 -1.1% -1.12% 380K

Professional, Scientific, and T...

(0.0% 1d) (24.1% 1m) (41.6% 1y) (0.0% 2d) (0.0% 3d) (-6.2% 7d) (-29.6% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 260,437,520
https://pyxisoncology.com
Sec Filling | Patents | 2021 employees

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

cancer t-cell

add to watch list Paper trade email alert is off

Quoin Pharmaceuticals Ltd - ADR

QNRX | $0.6589 -0.17% -0.17% 82K

Professional, Scientific, and T...

(0.0% 1d) (-22.4% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (-9.6% 7d) (224.64% volume)
Earnings Calendar:
Market Cap: $ 2,428,686
https://cellect.co
Sec Filling | Patents | 2020 employees

(IL) Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

ceiling t-cell

add to watch list Paper trade email alert is off

BIOXYTRAN, INC

BIXT A | $0.141 490.75% 55K

Professional, Scientific, and T...

(0.0% 1d) (27.2% 1m) (-70.5% 1y) (0.0% 2d) (0.0% 3d) (16.7% 7d) (-80.8% volume)
Earnings Calendar:
Market Cap: $ 24,531,466
https://www.bioxytraninc.com/
Sec Filling | Patents | 3 employees

(US) bioxytran, inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. the company's lead pharmaceutical drug candidate is bxt-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. its products also include bxt-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. the company was founded in 2017 and is headquartered in newton, massachusetts.

injection

add to watch list Paper trade email alert is off